XenoPort (XNPT) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	-14.56M
Depreciation and amortization
Accretion of investment discounts and amortization of investment premiums, net	0
Stock-based compensation expense	2.39M
Prepaids and other current and noncurrent assets	118K
Accounts payable	713K
Accrued compensation	-1.8M
Accrued restructuring charges
Accrued preclinical and clinical costs	0
Accrued unconsolidated joint operating activities
Other accrued liabilities	-152K
Deferred revenue	-284K
Deferred rent
Net cash provided by (used in) operating activities
Purchases of investments	-67.26M
Proceeds from maturities of investments	48.18M
Change in restricted investments
Purchases of property and equipment	-9K
Net cash provided by investing activities
Net cash provided by (used in) issuance of common stock and exercise of stock options	-287K
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents	-38.44M
Cash and cash equivalents at beginning of period	61.32M
Cash and cash equivalents at end of period	22.88M

Entities mentioned with XNPT

View All Entities